Simon Chandler

Chief Executive Officer, Rinri Therapeutics

Simon is the CEO of Rinri Therapeutics. Having been involved with the company since its inception, he has collaborated closely with the scientific founder and is responsible for the company's strategy, operations and financing. With a career spanning several blue-chip biotechnology and pharmaceutical development companies, Simon possesses extensive knowledge and experience in the life science and biotech sectors.

Before joining Rinri, Simon was an Investment Director at IP Group, a deep-tech venture capital fund. In this role, he specialized in early-stage investment and venture building, creating new companies based on world-class science. His experience at IP Group provided him with broad exposure to the life science market, including therapeutics, devices, tools, synthetic biology, and AI.

Simon is a firm believer in Rinri's technology having taken it from its academic roots to clinical trials within the next 12 months. He sees Rinri as being at the forefront of hearing loss therapeutic development and is confident in its potential to make a significant global impact on patients, healthcare, and the broader economy.

Simon holds a first-class BSc (Hons) in Biology from the University of Leeds, a PhD in Molecular Biology and Biochemistry from the University of York, and an MBA from Durham University

Rosie Lindup

Policy and Public Affairs Manager, BioIndustry Association

Previously, Rosie worked as a Senior Research Consultant at a Westminster-based public affairs agency, where she supported clients from a range of sectors, including pharmaceuticals, technology and financial services. Prior to that, Rosie worked as a Management Consultant at KPMG, where she assisted on financial and regulatory projects with large corporate clients. She has a BA in Human, Social and Political Sciences from the University of Cambridge.

Andrew Olaye

General Manager, UK and Ireland and Head of EMEA Market Access, Orchard Therapeutics

Andrew Olaye is General Manager, UK and Ireland as well as the Head of EMEA Market Access at Orchard Therapeutics. He has over 15 years of experience in commercial management,  pricing and reimbursement, market access, health economics, encompassing various roles of increasing responsibilities at Grunenthal, BioMarin, Vertex Pharmaceuticals and Orchard Therapeutics. During this time, he has successfully commercialised several innovative therapies for rare disease (including cell and gene therapies) across Europe and the Middle East.